MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.590
+0.040
+2.58%
After Hours: 1.570 -0.02 -1.26% 16:56 01/24 EST
OPEN
1.530
PREV CLOSE
1.550
HIGH
1.595
LOW
1.465
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
14.60
52 WEEK LOW
1.465
MARKET CAP
156.06M
P/E (TTM)
-1.0463
1D
5D
1M
3M
1Y
5Y
BRIEF-Adverum Biotechnologies Granted Orphan Drug Designation By FDA For Gene Therapy Candidate In Preclinical Development For The Treatment Of Blue Cone Monochromacy
reuters.com · 01/04 13:25
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
- ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) -REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targ...
GlobeNewswire · 01/04 13:00
Adverum granted FDA’s Orphan Drug Designation for treatment targeting color blindness
Adverum Biotechnologies (ADVM +9.7%) has received the Orphan Drug Designation from the FDA for a treatment directed at X-linked incomplete achromatopsia. The patients with achromatopsia suffer from partial or total
Seekingalpha · 01/03 16:57
Adverum Biotechnologies (NASDAQ:ADVM) investors are sitting on a loss of 84% if they invested a year ago
It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to...
Simply Wall St. · 01/01 11:02
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
Adverum Biotechnologies Inc (NASDAQ: ADVM) 
Benzinga · 12/21/2021 17:42
BRIEF-Adverum Biotechnologies Board Decreased Total Number Of Authorized Directors From Nine To Seven Directors
reuters.com · 12/21/2021 13:17
BRIEF-Adverum Biotechnologies Inc Finalizing Two-Dose Study Design For Phase 2 Trial Of ADVM-022 In Wet Amdwith Intention To Dose First Patient In Q32022
reuters.com · 12/21/2021 13:08
Adverum Biotechnologies Says Finalizing 2-Dose Study Design For Phase 2 Trial Of ADVN-022 In Wet AMD With Intention To Dose First Patient In Q3 2022
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of a review of its ADVM-022 program, outlined
Benzinga · 12/21/2021 13:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
20.00%Buy
80.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADVM stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.
High6.00
Average4.250
Low3.000
Current 1.590
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 168
Institutional Holdings: 80.94M
% Owned: 82.46%
Shares Outstanding: 98.15M
TypeInstitutionsShares
Increased
34
4.72M
New
13
1.82M
Decreased
39
11.95M
Sold Out
21
3.35M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Machado
President/Chief Executive Officer/Director
Laurent Fischer
Chief Financial Officer/Chief Accounting Officer
Rupert D Souza
Chief Operating Officer
Peter Soparkar
Chief Scientific Officer
Brigit Riley
Vice President
Jon Williams
Other
Julie Clark
Other
Star Seyedkazemi
Independent Director
Mark Lupher
Independent Director
James Scopa
Independent Director
Dawn Svoronos
Independent Director
Reed Tuckson
Independent Director
Scott Whitcup
No Data
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.